Sun Pharma's Strategic Horizon: Why an Innovative Portfolio Expansion Could Be Its Next Big Win

Sun Pharmaceutical Industries Ltd., a name synonymous with pharmaceuticals in India and increasingly, across the globe, appears to be charting a rather ambitious course. The company is actively bolstering its innovative drug pipeline, a strategic pivot that many analysts believe could significantly drive up its stock value. It's not just about incremental growth anymore; it's about making bold moves that promise substantial future returns.

One of the more recent and frankly, quite exciting developments, is Sun Pharma's exclusive in-licensing deal with LIB Therapeutics for Lerodalcibep. Now, this isn't just any new drug; we're talking about a cholesterol-lowering medication from the potent PCSK9 class. What makes this particularly noteworthy is that Sun Pharma has secured the rights for markets worldwide, save for the US and China. When you consider the global PCSK9 market is projected to hit around $7 billion in 2026, and this particular deal is estimated to unlock a whopping $3.7 billion market growing at an impressive 38% annually, well, it's clear this is a very big piece of the pie.

But Lerodalcibep isn't the only star in Sun Pharma's innovative constellation. Their existing portfolio already boasts some impressive performers. Take Ilumya, for instance, a plaque psoriasis drug that's currently their largest product. It clocked sales of $796 million in fiscal year 2026, showing a robust 17% year-over-year growth. And there's more potential on the horizon for Ilumya, with a USFDA approval for psoriatic arthritis looming as a near-term catalyst. Beyond that, drugs like Leqselvi for hair loss (alopecia areata) and Unloxcyt, a skin cancer formulation, are steadily ramping up. Not to forget Semaglutide, which recently secured approvals in multiple markets. All told, their innovative medicines segment collectively grew by a solid 16.8% to $1.42 billion in FY26 – quite a testament to their focused efforts.

Adding another layer to this ambitious strategy is the proposed acquisition of Organon, valued at a staggering $12 billion. While still awaiting completion, likely by early 2027, this move could be transformative. It's expected to dramatically expand Sun Pharma's scale across innovative medicines, women's health, and biosimilars, truly broadening its global footprint. Interestingly, this deal falls outside the scope of any existing US tariff agreements, meaning it's a separate, strategic play entirely.

Market watchers, it seems, are largely echoing this optimism. Brokerage firms like 360 ONE Capital Research commend the Lerodalcibep deal as a continuation of Sun Pharma's strong track record. Nomura, while noting earnings resilience, also cautions about broader macroeconomic factors like oil prices and geopolitics potentially weighing on valuations. Nevertheless, several analysts, including Robit Bhat and Hrishikesh Patole, highlight these innovative expansions as crucial near-term catalysts. We've seen 'buy' or 'add' ratings from multiple brokerages, with target prices ranging from ₹2,070 (Geojit Research) up to ₹2,250. Kotak Research, for its part, has an 'add' rating with a target of ₹2,150, also pointing out the US tariff deal that protects Sun Pharma’s US branded portfolio until January 20, 2029, and specifically excludes Medicare.

Currently, Sun Pharma's stock is trading at around ₹1,860, sitting at 27 times its FY28 earnings estimates. This valuation, coupled with the myriad of potential triggers—be it the scaling up of its US portfolio, the Lerodalcibep deal, the Organon acquisition, or even that crucial Ilumya approval—paints a rather compelling picture. The company is clearly not resting on its laurels; it's actively shaping its future, betting big on innovation. And if these strategic pieces fall into place, investors might just be in for a very rewarding ride.